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BACKGROUND 
 Since the description of Atrial Flutter (AFLt) a century ago, different discoveries has led 
to a better understanding of AFLt circuits and foci location and technological 
improvements have also facilitated curative treatment with radiofrequency catheter 
ablation (RFCA) 
Typical AFLt make up 22% of all 8,546 ablation procedures in the Spanish National 
Ablation's Registry (behind atrioventricular nodal reentrant tachycardia, accessory 
pathways but ahead of atrial fibrillation (AF)) 
 AFLt is considered to hold as much risk as AF for thromboembolic events (3-4% per 
year); AFLt also carries a proarrhythmic risk, and additionally, rhythm control and 
ventricular rate response can only hardly be achieved with medical treatment.  
 AFLt occurs 2.5 times more frequently in men than women; it is seen in 25% - 35% of 
patients with AF 
 
https://www.uptodate.com/contents/overview-of-atrial-flutter 
https://online.epocrates.com/diseases/18323/Atrial-flutter/Epidemiology 
https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-11/Atrial-flutter-common-and-main-atypical-forms 
 
INTRODUCTION 1.9. 
Typical AFLt  (Type I Atrial Flutter ,organised atrial tachycardia) is defined as a 
macroreentry tachycardia confined to the right atrium 
This arrhythmia has a 200-260 ms cycle length, although it may fluctuate 
depending on patient's previous treatment or ablation, congenital heart 
disease, etc.  
Ventricular rate response will be limited by the atrioventricular (AV) node 
conductions, usually presenting a 2:1 or 3:1 response, during AFLt 
https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-11/Atrial-flutter-common-and-main-atypical-forms 
INTRODUCTION 2.9. 
Typical AFLt  originates in a well-known circuit around the tricuspid annulus limited by 
anatomical barriers such as both the superior and inferior cava veins, the coronary 
sinus and crista terminalis; the wave front may rotate around this circuit 
counterclockwise (anticlockwise) or clockwise (see next slide) 
Anticlockwise Reentry is the commonest form of atrial flutter (90% of cases) 
Retrograde atrial conduction produces: 
Inverted flutter waves in leads II,III, aVF 
Positive flutter waves in V1 – may resemble upright P waves 
Clockwise Reentry uncommon variant produces the opposite pattern: 
Positive flutter waves in leads II, III, aVF 
Broad, inverted flutter waves in V1 
 
https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-11/Atrial-flutter-common-and-main-atypical-forms 
https://lifeinthefastlane.com/ecg-library/atrial-flutter/ 
INTRODUCTION 3.9. 
https://lifeinthefastlane.com/ecg-library/atrial-flutter/ 
AFLt with High-Grade AV Block 
There is anticlockwise flutter with marked AV block (varying from 5:1 up to 8:1). 
The very low ventricular rate suggests treatment with AV nodal blocking drugs (e.g. digoxin, beta-blockers); 
other possibilities could include intrinsic conducting system disease (true “AV block”) or electrolyte 
abnormality (e.g. hyperkalaemia) 
 
INTRODUCTION 4.9. 
http://www.ems12lead.com/2015/12/28/12-rhythms-of-christmas-atrial-flutter/ 
AFLt with Variable Block 
The block varies between 2:1 and 4:1 
The presence of positive flutter waves in lead II suggests a clockwise re-entry circuit 
INTRODUCTION 5.9. 
Some conditions may make the ECG diagnosis difficult: 
Scarred atria with low areas of voltage could mimic isoelectric baseline despite atrial 
continuous electrical activity (see next slide) 
Concomitant circuits could also change the typical atrial appearance 
Both high and irregular ventricular rate responses may make the diagnosis difficult; in the first 
case, vagal maneuvers or AV node blocking drugs, such as adenosine, may be useful, in the 
second case, a regular irregularity has to be always ruled out 
Electrophysiological studies (EPs) are indicated: 
In AFLt recurrences despite medical treatment (Class I indication) 
After the first episode of AFLt (Class IIa indication), especially in those presenting with poor 
hemodynamic tolerance or tachymiocardiopathy 
 https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-11/Atrial-flutter-common-and-main-atypical-forms 
INTRODUCTION 6.9. 
http://www.ems12lead.com/2015/12/28/12-rhythms-of-christmas-atrial-flutter 
AFLt with F-waves only visible in V1 
INTRODUCTION 7.9. 
The ablation procedure's main target is to achieve bidirectional block through the CTI  
Acute success rate is almost 95% in the registries 
 However, at 5 year follow-up almost 70% of these patients might develop AF or 
atypical AFLt, which is probably related to the baseline characteristics, structural heart 
disease and uncontrolled risk factors 
https://www.escardio.org/Journals/E-Journal-of-Cardiology-Practice/Volume-11/Atrial-flutter-common-and-main-atypical-forms 
INTRODUCTION 8.9.: CATHETER  ABLATION 
OF CTI  
https://www.youtube.com/watc
h?v=1p0HUNmsSkU 
INTRODUCTION 9.9. 
Cardiosclerosis (from Greek «kardia» - "heart" and «sklerosis» - "condensation"; the 
synonymic name - myocardiosclerosis) - partial replacement of a fabric of a 
myocardium by a connecting fabric 
Differently, cardiosclerosis - formation of a cicatricial fabric in a muscle of heart 
which replaces with itself a myocardium and it is capable to deform valves of heart 
hypertension symptoms 
Post myocarditis cardiosclerosis occurs mainly in the population aged 20 to 40 
years; the cause of its development is the prevalence of infectious diseases, allergic 
reactions and other inflammatory or chronic processes in the body 
Post myocarditis cardiosclerosis, like atherosclerotic, is mainly diffuse 
http://brulanta.com/health/cardiosclerosis-symptoms-and-treatment/ 
http://www.8med.ru/view_article.php?id=42 
 
OUR CLINICAL CASE 
 Patient A is a 39 year old employed man, admitted to the hospital on the 
19th of September, 2017 
 
 
MAIN COMPLAINTS 
 Palpitations that was not evidenced to be connected with physical 
exercises, arrhythmias 
 Breathlessness while ascending the stair case to the third floor and 
ANAMNESIS OF THE DISEASE 1.2. 
 
 Over a year noticed increased blood pressure (max 150/100 mmHg, valsartan was 
prescribed to lower BP to 120/80mmHg) 
 20/03/2017 –upper respiratory tract infection (URTI), was treated by himself 
 After one week of URTI, patient presented to the regional hospital with leg edema, 
tiredness, palpitations and cough with rose sputum; was admitted to a hospital with 
preliminary diagnosis: Dilated cardiomyopathy, paroxysmal AFLt; treatment 
commenced in the hospital with amiodarone 200 mg/d, carvedilol 6.25mg/bd and 
rivaroxaban 20mg/d; transferred to a specialist hospital where was improved heart failure 
signs; in spite of treatment tachyform of AFLt persisted 
ANAMNESIS OF THE DISEASE 2.2. 
 
22/06/2017–04/07/2017 was admitted to cardiological department where diagnosis was 
made: Subacute (27/03/17) diffuse myocarditis unknown etiology, severe severity; 
AFLt, permanent form. Exudative pericarditis (27/03/17) and was discharged from 
the hospital with some improvement of symptoms (intook amiodarone 200 mg/d, 
carvedilol 6.25mg/bd and rivaroxaban 20mg/qd, valsartan 80 mg/d) 
 19/09/17 – admitted to the Kharkiv clinical hospital on railway transport #1 of 
"Healthcare Center" subdivision of  public joint-stock company "Ukrainian railway" for 
reevaluation and correction of treatment plan 
ANAMNESIS VITAE 
 The patient due to his sedentary lifestyle and high calorie diet gained 
approximately 10kg in the course of the year 
 He was diagnosed with hepatitis A as a child 
 There is negative history of tuberculosis, has no known allergic reactions to 
drugs 
There is a positive family history of cardiovascular disease, his father was 
diagnosed with myocardial infarction at age 56 
Patient admitted to smoking about 5 sticks of cigarette daily and drinking a small 
quantity of alcohol occasionally 
OBJECTIVE EXAMINATION 1.2 
General condition is relatively satisfactory, no evidence of physical distress, 
clear consciousness; height – 171 sm, weight – 128 kg; BMI= 44 kg/m2 
Skin and visible mucous membranes are clean, pale pink and acyanotic, but 
face was flushed 
Peripheral lymph nodes are not palpable 
Thyroid gland is painless and not palpable 
Cardiovascular system: heart rate=90bpm, pulse=90 bpm;  
BP left hand = 120/85 mmHg, right hand = 130/90 mmHg (on the background of 
antihypertensive therapy) 
On auscultation, the apex beat is shifted to the left, second heart sound is 
accentuated over the aorta 
 
 
OBJECTIVE EXAMINATION 2.2 
Respiratory system: RR=17breaths/min; auscultation - weakened 
vesicular breathing, no adventitious sounds 
Abdomen is enlarged due to subcutaneous fat, painless on palpation, liver 
protrudes about 2-3cm below the costal arch margin, painless on palpation 
There is symmetric edema of the lower limbs 
Pasternasky’s sign is negative 
PRELIMINARY DIAGNOSIS 
Post myocarditis cardiosclerosis  
AFLt, persistent form, tachysystolic 
 Chronic heart failure 
Obesity 
 
RECOMMENDED EXAMINATIONS 
 Complete blood test 
 General urine test 
 ECG 
 EchoCG 
 24-h ambulatory ECG monitoring 
 Coagulogram 
 TSH, T4, anti-thyroid gland antibodies 
(anti-TG Ab)  
 Fasting glucose level 
 Biochemical blood test (ALT, AST, AP, 
bilirubin)  
    Renal function tests (creatinine) 
     Consultation of ophthalmologist, 
arrhythmologist 
 Blood lipid spectrum 
 Ultrasound of abdomen 
 Glycated hemoglobin (HbA1C) 
 Blood electrolytes 
 Biomarkers: troponin and BNP levels 
 Serum cardiac autoantibodies 
 
*was made in the hospital 
COMMON BLOOD TEST (20/09/2017) 
Measure Result Rate Measure Result Rate 
Hemoglobin (Hb) 165 130 – 160 g/L Segmented 
Neutrophils 
62.5 47.0 -72.0 
Neutrophils 
Erythrocyte 5.58 4.0 – 5.0 T/L Eosinophils 1.7% 0.5 – 5.0% 
Color Index 0.92 0.8 -1.2 Basophils 1.3% 0 – 1.0% 
Leukocytes 7.2 4.0 – 9.0 g/L Monocytes 7.3% 3.0 -11.0% 
ESR 8 M 1-10 mm/h Lymphocytes 27.2% 19.0 -37.0% 
Platelets 244 180 -320 g/L Hematocrit 48.9% 40 – 48% 
Neutrophils 62.5 48.06 – 78% 
Conclusion: A rise in Hemoglobin, erythrocyte and basophils level in the blood 
GENERAL URINE TEST (20/09/2017) 
MEASURE RESULT NORMAL RANGE 
SPECIFIC GRAVITY 1.015 1.001 – 1.040 
pH 5.0 5.0 – 7.0 
PROTEIN ABSENT To 0.033g/l 
GLUCOSE ABSENT ABSENT 
EPITHELIUM 
TRANSITION 
ABSENT Not detected 
BACTERIA ABSENT Not detected 
Conclusion: Normal 
BIOCHEMICAL BLOOD TEST (20/09/2017) 
MEASURE RESULT RANGE 
Total Bilirubin 6.0 1.7 – 21mmol/l 
AST 20.1  To 37 U/L 
ALT 27.0 To 41 U/L 
Creatinine 70 62 – 106 µmol/L 
Conclusion: Normal 
GLOMERULAR FILTRATION RATE 
ESTIMATED GFR NORMAL RANGE 
The Modification of Diet in Renal Disease (MDRD) 
(GFR (mL/min/1.73 m2 ) = 175 × (Scr ) -1.154 × (Age)-
0.203 × (0.742 if female) × (1.212 if African American)) 
 
Study Equation 109 mL/min/1.73 m² 
Age (30 - 39) 67-125 ml/min/1.73 m2 
Conclusion: Normal kidney function 
FASTING GLUCOSE TEST (20/09/2017) 
MEASURE RESULT NORMAL RANGE 
Fasting Blood Glucose 6.22 3.9 – 6.1 mmol/L 
Conclusion: Normal 
ULTRASOUND OF ABDOMEN 
Hepatomegaly with steatohepatosis 
Diffuse changes of liver and pancreas 
Sludge in the gallbladder 
THYROID FUNCTION TESTS (20/09/17) 
MEASURE RESULT RANGE 
TSH 2.15 0.27-4.2µmol/ml 
Free T3 2.84 2.0-4.4pg/ml 
Free T4 1.13 0.93-1.17ng/dl 
Anti-TPO 17.3 To 34 MO/ml 
Antibodies to 
Thyrogloblulin 
18.54 To 115 MO/ml 
Thyrotropin receptor, 
antiter IgG 
<0.3 to 1.75 MO/l 
Conclusion: Normal 
BLOOD LIPID SPECTRUM (20/09/2017) 
MEASURE RESULT RATE 
TOTAL CHOLESTEROL 5.10 ≤ 5.2 mmol/l  
VLDL 1.19 < 1.0 mmol/l 
LDL 3.08 <3.5 mmol/l 
HDL- Cholesterol levels 0.82 >0.9 mmol/l  
Triglycerides 2.65 <2.3 mmol/l 
COEFFICIENT of 
atherogenecity 
5.21 To 3.0 mmol/l 
Conclusion: Dyslipidemia II b type 
ECG WITH TYPICAL AFLT   
Conclusion: AFLt with AV node conductions from 3:1 to 5:1 response with low areas of 
F waves voltage ; heart rate 75 bpm 
24-H AMBULATORY ECG WITH TYPICAL AFLT 
AND PREMATURE VENTRICLE CONTRACTION 
24-H AMBULATORY ECG MONITORING: 
CONCLUSION  
▶ During the 18 hour monitoring AFLt was registered and with 
a mean heart rate of 81 bpm (maximum HR 116 bpm, 
minimum HR 63 bpm)  
▶ Was recorded: ventricular premature contractions (total 
167) 
▶ Ischemic changes have not been identified  
 
ECHOCARDIOGRAPHY 1.2. 
Name Result before 
Ablation 
Result after 
ablation 
Normal 
1) Acoustic window poor normal 
2) Aorta 30.6 20 – 37 mm 
3) Aortic valve 18.8 17 – 26 mm 
4) Left Atrium 41 To 38 mm 
5) Mitral Valve No regurgitation No regurgitation 
6) Posterior Wall of 
the LV 
12  6 -11mm 
7) Interventricular 
Septum 
12 6 – 11mm 
8) Right Ventricle 27.5 D.: (9-26 mm)  
ECHOCARDIOGRAPHY 2.2. 
Name Result before 
ablation 
Result after 
ablation 
Normal 
9) Right atrium 44 <38mm 
10) Tricuspid valve Regurgitation 1st 
degree 
No regurgitation 
11) Ejection 
Fraction 
66 55 – 78% 
Conclusion: Sclerotic changes of the aorta, aortic and mitral cusps, dilatation of both 
atriums, dilatation of right ventricle, hypertrophy of left ventricle; ECHO signs of 
diastolic dysfunction 
BASIC CLINICAL SYNDROMES 
▶ Atherosclerosis (sclerotic changes of aorta and aortic valve)  
▶ Arterial hypertension  
▶ Arrhythmias 
▶ Heart failure  
▶ Metabolic syndrome 
▶ Hypertensive heart (LVH, atrial enlargement, diastolic 
dysfunction)  
 
CLINICAL DIAGNOSIS ACCORDING TO 
CURRENT CLASSIFICATIONS 
 
CARDIOSCLEROSIS CLASSIFICATION 
http://brulanta.com/health/cardiosclerosis-symptoms-and-treatment/ 
Forms: 
• Focalized cardiosclerosis 
• Diffuse cardiosclerosis 
Etiology: 
• Postinfarction cardiosclerosis , formed as a result of an experienced 
attack of myocardial infarction 
• Atherosclerotic cardiosclerosis is formed on the basis of coronary artery 
atherosclerosis 
• Post myocarditis cardiosclerosis is formed due to the development of 
inflammatory processes in the myocardium 
 
 
PATTERNS OF AF/AFLT 
AF/AFLt pattern Definition 
First diagnosed 
AF/AFLt 
 
AF/AFLt that has not been diagnosed before, irrespective of the duration of the 
arrhythmia or the presence and severity of AF-related symptoms 
Paroxysmal AF/AFLt 
Self-terminating, in most cases within 48 hours. Some AF/AFLt paroxysms may 
continue for up to 7 days. AF/AFLt episodes that are cardioverted within 7 days 
should be considered paroxysmal 
Persistent AF/AFLt 
AF/AFLt that lasts longer than 7 days, including episodes that are terminated by 
cardioversion, either with drugs or by direct current cardioversion, after 7 days or 
more 
Long-standing 
persistent AF/AFLt 
Continuous AF/AFLt lasting for ≥1 year when it is decided 
to adopt a rhythm control strategy 
Permanent AF/AFLt 
AF/AFLt that is accepted by the patient (and physician). Hence, rhythm control 
interventions are, by AF/AFLt. Should a rhythm control strategy be adopted, the 
arrhythmia would be re-classified as ‘long-standing definition, not pursued in 
patients with permanent persistent AF/AFLt’ 
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS 
MODIFIED EUROPEAN HEART RHYTHM ASSOCIATION 
SYMPTOM SCALE (MODIFIED FROM WYNN ET AL) 
2016 ESC Guidelines for the management of atrial fibrillation developed  in collaboration withEACTS 
AFLT/FIBRILLATION CHA2-DS2-VASC SCORE FOR 
STROKE  
Score CHA2DS2-VASc Risk Criteria 
1 point Congestive heart failure 
1 point Hypertension 
2 points Age ≥75 years 
1 point Diabetes mellitus 
2 points Stroke/Transient Ischemic Attack/Thromboembolic event 
1 point Vascular disease (prior MI, PAD, or aortic plaque) 
1 point Age 65 to 74 years 
1 point Sex category (i.e, female sex) 
https://emedicine.medscape.com/article/2172597-overview 
Conclusion: patient’s CHA2-DS2-VASc score for stroke=2; risk of developing a 
stroke within a year is only 2.2% 
MODIFIABLE AND NON-MODIFIABLE RISK FACTORS FOR BLEEDING IN 
ANTICOAGULATED PATIENTS BASED ON BLEEDING RISK SCORES   
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS 
Category Systolic Diastolic 
Optimal <120 and <80 
Normal 120-129 and/or 80-84 
High normal 130-139 and/or 85-89 
Grade 1 hypertension 140-159 and/or 90-99 
Grade 2 hypertension 160-179 and/or 100-109 
Grade 3 hypertension ≥180 and/or ≥110 
Isolated systolic 
hypertension 
≥140 and <90 
CLASSIFICATION OF OFFICE BLOOD 
PRESSURE LEVELS (MMHG) 
https://academic.oup.com/eurheartj/article/34/28/2159/451304 
TREATMENT RECOMMENDATIONS BASED 
ON CHA2DS2-VASC SCORE 
CHA2DS2-VASc Score Recommendation 
0 None 
1 None or aspirin or OAC 
2 or more 
 
OAC 
Conclusion: patient should be placed on oral anticoagulant to 
further reduce stroke risk 
https://emedicine.medscape.com/article/2172597-overview 
AMERICAN HEART ASSOCIATION HEART 
FAILURE STAGES 
http://www.heart.org/HEARTORG/Conditions/HeartFailure/AboutHeartFailure/Classes-of-Heart-Failure_UCM_306328_Article.jsp#.WhPZMd-WbIU 
NEW YORK HEART ASSOCIATION(NYHA) 
HEART FAILURE CLASSIFICATION SYSTEM 
https://www.intechopen.com/books/primary-care-in-practice-integration-is-needed/integrated-care-for-heart-failure-in-primary-care 
DEFINITION OF HEART FAILURE WITH 
PRESERVED EJECTION FRACTION (HFPEF) 
2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 
CARDIOVASCULAR RISK STRATIFICATION 
CHART WITH RECOMMENDED FOLLOW-UP 
FREQUENCY FOR EACH CATEGORY 
https://www.researchgate.net/figure/38056846_fig1_Cardiovascular-risk-stratification-chart-with-recommended-follow-up-frequency-for-each 
LIPOPROTEIN PATTERNS (FREDRICKSON 
PHENOTYPES) 
 
Phenotype 
 
Elevated Lipoprotein(s) 
 
Elevated Lipids 
 
Phenotype 
 
Elevated Lipoprotein(s) 
 
Elevated Lipids 
I Chylomicrons TGs 
IIa LDL Cholesterol 
IIb LDL and VLDL TGs and cholesterol 
III VLDL and chylomicron 
remnants 
TGs and cholesterol 
IV VLDL TGs 
V Chylomicrons and VLDL TGs and cholesterol 
LDL = low-density lipoprotein; TGs = triglycerides; VLDL = very-low-density 
lipoprotein. 
https://www.msdmanuals.com/professional/endocrine-and-metabolic-disorders/lipid-disorders/dyslipidemia#v989709 
WAIST TO HIP RATIO 
http://www.waist-to-hip-ratio.com/chart 
CLASSIFICATION OF OVERWEIGHT AND 
OBESITY BY BMI, WAIST CIRCUMFERENCE 
AND ASSOCIATED DISEASE RISK 
 
https://www.canada.ca/en/health-canada/services/food-nutrition/healthy-eating/healthy-weights/canadian-guidelines-body-weight-classification-adults/body-mass-index-nomogram.html 
DEFINITIONS OF METABOLIC SYNDROME 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2675814/ 
PATIENT COMPLETE MAIN DIAGNOSIS 
MAIN:  
DIFFUSE POST MYOCARDITIS 
CARDIOSCLEROSIS 
PERSISTENT AFLT, EUSYSTOLIC FORM, 
EHRA III SCORE 
CHA2-S2-VASc SCORE – 2 
ESSENTIAL ARTERIAL HYPERTENSION, 
GRADE 1 
HEART FAILURE WITH PRESERVED 
EJECTION FRACTION II FC, STAGE B 
HIGH ADDED CARDIOVASCULAR RISK 
DYSLIPIDEMIA-IIB 
 
 
• Nonalcoholic fatty liver disease 
(NAFLD)  
• OBESITY CLASS III 
 
CO-MORBIDITY 
TREATMENT 
 GOAL BASED FOLLOW-UP 
2016 ESC Guidelines for the management of atrial fibrillation 
RISK FACTOR MANAGEMENT 
Expert Review of Cardiovascular Therapy 
LIFESTYLE MODIFICATION 
Intensive weight reduction in addition to the management of other 
cardiovascular risk factors (in the range of 10–15 kg weight loss 
achieved), led to fewer AF/AFLt recurrences and symptoms compared 
with an approach based on general advice in obese patients with 
AF/AFLt  
DASH diet  
Smoking cessation 
Control of compliance to medical recommendations 
2016 ESC Guidelines for the management of atrial fibrillation 
STROKE PREVENTION IN AF/AFLT 1.2 
Controlled trials studying OAC in AF/AFLt patients have been enriched for patients at 
high risk of stroke, and hence there is strong evidence that patients with a CHA2DS2- 
VASc risk score of 2 or more in men, and 3 or more in women, benefit from OAC 
NOACs, including the direct thrombin inhibitor dabigatran and the factor Xa inhibitors 
apixaban, edoxaban, and rivaroxaban, are suitable alternatives to VKAs for stroke 
prevention in AF/ AFLt 
Both VKAs and NOACs are effective for the prevention of stroke in AF/ AFLt 
Rivaroxaban was non-inferior to warfarin for the prevention of stroke and systemic 
embolism in the intent-to-treat  analysis, while the per-protocol on-treatment analysis 
achieved statistical superiority with a 21% reduction in stroke or systemic embolism 
compared with warfarin 
2016 ESC Guidelines for the management of atrial fibrillation 
STROKE PREVENTION IN AF/AFLT 2.2 
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS 
RHYTHM CONTROL 
Restoring and maintaining sinus rhythm is an integral part of  AF/ 
AFLt  management 
Antiarrhythmic drugs approximately double the rate of sinus rhythm 
compared with placebo 
RFCA or combination therapy is often effective when antiarrhythmic 
drugs fail 
 
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS 
ORAL ANTIARRYTHMIC DRUGS USED FOR 
MAINTANING SINUS RHYTHM 
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration withEACTS 
TREATMENT OF NAFLD 
 Loss of at least 3-5% of body weight appears necessary to improve 
steatosis, but a greater weight loss (up to 10%) may be needed to improve 
necroin- flammation 
 Patients with NAFLD and NASH are at increased risk for cardiovascular 
disease and several studies have established cardiovascular disease as 
their most common cause of death 
 Statins are an important class of agents to treat dyslipidemia, and yet there 
is continued reluctance to use statins in patients with suspected or 
established chronic liver disease, including NAFLD  
http://ps70.sb.marqui.com/files/Professional_Education___Partnerships/Information___Resources_for_HCP/AASLD_CPG_for_NAFLD_-_June_2012.pdf 
PATIENT’S COMPLETE DRUG TREATMENT 
TORASEMIDE 2,5 mg daily 
VALSARTAN - 40 – 80 mg twice daily under BP control 
AMIODARONE - 200mg twice daily  
CARVEDILOL -12,5 mg twice daily under BP and heart rate control  
RIVAROXABAN - 20mg daily 
ROSUVASTATIN - 10 mg daily under control of lipids level, ALT, AST 
Despite this treatment there was no affect in restoring sinus rhythm 
Patient was consulted by arrhythmologist with conclusion:  
Typical AFLt, persistent form 
 Recommended RFCA CTI 
2016 ESC Guidelines for the management of atrial fibrillation 
PATIENT CHOICE- HYBRID THERAPY (RFCA+AAD) 
Patient was transferred to SI «Zaycev V.T. Institute of General and 
Urgent Surgery NAMS of Ukraine» for RFCA 29/09/17 
02/10/17 was performed RFCA of CTI (time 180 msec) 
Sinus rhythm was restored 
Postoperative period without complications 
CHECK-UP 3 DAYS AFTER RFCA 1.7. 
No episodes of arrhythmia 
ECG (see next slide) 
Sinus rhythm, HR- 71bpm 
Normal cardiac axis 
Signs of left ventricular hypertrophy, PQ -170ms, QRS- 75ms, QT- 
360ms 
CHECK-UP 3 DAYS AFTER RFCA (ECG)2.7. 
CHECK-UP 3 DAYS AFTER RFCA 3.7. 
COMMON BLOOD TEST (29/09/2017) 
Measure Result Rate Measure Result Rate 
Hemoglobin 
(Hb) 
160 130 – 160 
g/L 
Segmented 
Neutrophils 
62.5 47.0 -72.0 
Neutrophils 
Erythrocyte 5.0 4.0 – 5.0 T/L Eosinophils 2% 0.5 – 5.0% 
Color Index 0.92 0.8 -1.2 Basophils 1% 0 – 1.0% 
Leukocytes 6.9 4.0 – 9.0 g/L Monocytes 7.3% 3.0 -11.0% 
ESR 8 M 1-10 mm/h Lymphocyte
s 
27.2% 19.0 -37.0% 
Platelets 244 180 -320 g/L Hematocrit 48.9% 40 – 48% 
Neutrophils 62.5 48.06 – 78% 
Conclusion: Normal 
CHECK-UP 3 DAYS AFTER RFCA 4.7. 
BIOCHEMICAL TESTS (29/09/2017) 
MEASURE RESULT NORMAL RANGE 
Fasting Blood Glucose 6.2 3.9 – 6.1 mmol/L 
Prothrombin Index 85 78-142% 
Conclusion: Normal 
CHECK-UP 3 DAYS AFTER RFCA 5.7. 
ECHOCARDIOGRAPHY AFTER RFCA 1.2. 
Name Result before 
Ablation 
Result after 
ablation 
Normal 
1) Acoustic window poor normal 
2) Aorta 31 20 – 37 mm 
3) Aortic valve 19 17 – 26 mm 
4) Left Atrium 42 To 38 mm 
5) Mitral Valve Regurgitation 1st 
degree 
No regurgitation 
6) Posterior Wall of 
the LV 
12  6 -11mm 
7) Interventricular 
Septum 
12 6 – 11mm 
8) Right Ventricle 27.0 D.: (9-26 mm)  
CHECK-UP 3 DAYS AFTER RFCA 6.7. 
ECHOCARDIOGRAPHY AFTER RFCA 2.2. 
Name Result before 
ablation 
Result after 
ablation 
Normal 
9) Right atrium 44 <38mm 
10) Tricuspid valve Regurgitation 1st 
degree 
No regurgitation 
11) Ejection 
Fraction 
74 55 – 78% 
Conclusion: Mild dilatation of both atriums, dilatation of right ventricle, hypertrophy of 
left ventricle  
CHECK-UP 3 DAYS AFTER RFCA 7.7.: HEART RATE 
VARIABILITY (HRV)  
Conclusion: 
The rhythmogram of HRV is characterized by weakly 
expressed fast and slow waves, as well as the 
presence of very slow waves. This character of the 
rhythmogram and the structure of HRV indicates the 
stabilization of the heart rhythm with the transition of 
its regulation from the reflex-vegetative level to a 
lower humoral - metabolic, unable to quickly provide 
homeostasis. Functional capabilities of the heart are 
reduced.  
Range of HRV Rhythmogram of HRV 
OUR RECOMMENDED POST – RFCA 
TREATMENT  
VALSARTAN - 40 – 80 mg twice daily under BP control 
AMIODARONE – 200 mg daily one month under ECG control  
CARVEDILOL - 25 mg twice daily under BP and heart rate control 
with increasement to maximal tolerated dosage to improve the 
recovery (remission?) after myocarditis 
RIVAROXABAN – 20 mg daily 
ROSUVASTATIN - 10 mg daily under control of lipids level, ALT, AST 
ADDITIONAL RECOMMENDED  
EXAMINATIONS 
 
 Repeat 24h – ECG monitoring in a 12 month  
 Blood electrolytes (K, Na) 
 Contrast-enhanced cardiovascular magnetic  
resonance imaging 
 HbA1C 
 Glucose tolerance test 
 
 
 
PROGNOSIS 
• Prognosis for life - compliance to doctor's 
appointments – satisfactory  
• The prognosis for recovery - satisfactory 
CONCLUSION 1.2. 
1. RFCA of the CTI is one of the most frequently performed procedures in 
electrophysiology and, as it was shown in current case,  has a very good result in 
rhythm control strategy in early postoperative period 
2. Performing common AFLt catheter ablation under oral anticoagulation is 
associated with low risk of complications that found a confirmation in our clinical 
case 
3. AF inducibility in patients undergoing CTI AFL without history of AF is a strong 
predictor of AF occurrence in the future; appropriate cardiology follow-up must be 
encouraged in this high-risk population as stroke prevention strategies can be 
appropriately introduced in a timely matter especially in patients with elevated 
CHA2DS2-VASc scores (≥2); that is why our patient will undergo complete 
cardiology follow-up several times  after RFCA  
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4356719/ 
https://www.futuremedicine.com/doi/abs/10.2217/fca-2017-0007?rfr_dat=cr_pub%3Dpubmed&url_ver=Z39.88-2003&rfr_id=ori%3Arid%3Acrossref.org& 
https://www.ncbi.nlm.nih.gov/pubmed/28606678 
CONCLUSION 2.2. 
4. To improve effectiveness of intervention therapy, like RFCA,  and prevent the 
recurrence of AFLt/AF in future patients need additional medical support by 
antiarrhythmic drugs  
5. Patients should be informed and know about signs and symptoms of late 
complications to allow swift referral for treatment 
6. Patients with fulminant myocarditis and hemodynamic compromise at presentation 
have better outcomes than those with acute nonfulminant myocarditis and this 
(fulminant) form we suspect in our patient’s according history of disease and presume 
the same outcome 
 
2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS 
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2770911/#R50 

